Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database.

ABSTRACT:

Background

Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding. The objective of this study is to determine the relative risk of cardiovascular adverse events or haemorrhages in patients with peripheral artery disease treated with cilostazol in comparison to pentoxifylline users.

Methods

Population-based cohort study including all individuals older than 40 who initiated cilostazol or pentoxifylline during 2009-2011 in SIDIAP database. The two treatment groups were matched through propensity score (PS).

Results

Nine thousand one hundred twenty-nine patients met inclusion criteria and after PS matching, there were 2905 patients in each group. 76% of patients were men, with similar mean ages in both groups (68.8 f

SUBMITTER: Real J 

PROVIDER: S-EPMC5941464 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature